Aliases & Classifications for Uveal Diseases

MalaCards integrated aliases for Uveal Diseases:

Name: Uveal Diseases 49 69

Classifications:



External Ids:

UMLS 69 C0042161

Summaries for Uveal Diseases

MalaCards based summary : Uveal Diseases is related to allergic hypersensitivity disease and diphtheria, and has symptoms including mydriasis and eye manifestations. The drugs Heparin and Dexamethasone have been mentioned in the context of this disorder. Affiliated tissues include eye, endothelial and liver.

Related Diseases for Uveal Diseases

Diseases related to Uveal Diseases via text searches within MalaCards or GeneCards Suite gene sharing:

# Related Disease Score Top Affiliating Genes
1 allergic hypersensitivity disease 9.8
2 diphtheria 9.6
3 uveitis 9.6
4 retinitis 9.6

Symptoms & Phenotypes for Uveal Diseases

UMLS symptoms related to Uveal Diseases:


mydriasis, eye manifestations

Drugs & Therapeutics for Uveal Diseases

Drugs for Uveal Diseases (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 345)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Heparin Approved, Investigational Phase 4,Phase 2 9005-49-6 46507594 772
2
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-02-2 5743
3
Methotrexate Approved Phase 4,Phase 3,Phase 2,Phase 1 1959-05-2, 59-05-2 126941
4
Mycophenolic acid Approved Phase 4,Phase 3 24280-93-1 446541
5
Mycophenolate mofetil Approved, Investigational Phase 4,Phase 3 128794-94-5 5281078
6
Ganciclovir Approved, Investigational Phase 4 82410-32-0 3454
7
Azathioprine Approved Phase 4,Phase 2 446-86-6 2265
8
Infliximab Approved Phase 4,Phase 3,Phase 1,Phase 2 170277-31-3
9
Timolol Approved Phase 4,Phase 3 26839-75-8 5478 33624
10
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-24-8 5755
11
Iodine Approved, Investigational Phase 4,Phase 2,Phase 1 7553-56-2 807
12
Verteporfin Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 129497-78-5
13
Triamcinolone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 124-94-7 31307
14
Latanoprost Approved, Investigational Phase 4 130209-82-4 5311221 5282380
15
Ranibizumab Approved Phase 4,Phase 3,Phase 2,Phase 1 347396-82-1 459903
16
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 83-43-2 6741
17
Fluocinolone Acetonide Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 67-73-2 6215
18
Bevacizumab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 216974-75-3
19
Povidone-iodine Approved Phase 4,Phase 3 25655-41-8
20
Povidone Approved Phase 4 9003-39-8
21
Tacrolimus Approved, Investigational Phase 4 104987-11-3 445643 439492
22
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2 50-18-0, 6055-19-2 2907
23
Chlorambucil Approved Phase 4 305-03-3 2708
24
Tamsulosin Approved, Investigational Phase 4 106133-20-4 129211
25
Ephedrine Approved Phase 4,Phase 3,Phase 1,Phase 2 299-42-3 9294
26
Tobramycin Approved, Investigational Phase 4 32986-56-4 36294 5496
27
Dorzolamide Approved Phase 4 120279-96-1 5284549 3154
28
Daclizumab Approved, Investigational Phase 4,Phase 2,Phase 1 152923-56-3
29
Pseudoephedrine Approved Phase 4,Phase 3,Phase 1,Phase 2 90-82-4 7028
30
Alfuzosin Approved, Investigational Phase 4 81403-80-7 2092
31
Bimatoprost Approved, Investigational Phase 4 155206-00-1 5311027
32
Travoprost Approved Phase 4,Phase 3 157283-68-6 5282226
33
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2 53-03-2 5865
34
Difluprednate Approved Phase 4,Phase 3,Phase 2 23674-86-4 443936
35
Ofloxacin Approved Phase 4 82419-36-1 4583
36
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
37
Certolizumab pegol Approved Phase 4 428863-50-7
38
Nepafenac Approved, Investigational Phase 4 78281-72-8 151075
39
leucovorin Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1 58-05-9 143 6006
40
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 59-30-3 6037
41
Lactitol Investigational Phase 4 585-86-4 3871
42
Bromfenac Approved July 1997 Phase 4 91714-94-2 60726
43
Maleic acid Experimental Phase 4,Phase 2 110-16-7 444266
44 triamcinolone acetonide Phase 4,Phase 2,Phase 3,Phase 1
45 cadexomer iodine Phase 4,Phase 2,Phase 1
46 calcium heparin Phase 4,Phase 2
47 Prednisolone acetate Phase 4,Phase 3,Phase 2,Phase 1
48 Dexamethasone acetate Phase 4,Phase 3,Phase 2,Phase 1 1177-87-3
49 Analgesics Phase 4,Phase 3,Phase 2,Phase 1
50 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 614)

# Name Status NCT ID Phase Drugs
1 Aflibercept Intravitreal Injection for Myopic Choroidal Neovascularization Unknown status NCT02033018 Phase 4 Aflibercept Injection
2 Posterior Subtenon Versus Intravitreal Injection of Triamcinolone Acetonide for Treatment of Uveitic Cystoid Macular Edema Unknown status NCT02598869 Phase 4 Triamcinolone Acetonide
3 Evaluating Results of Neusidl Corneal Inserter in Descemet's Stripping Automated Endothelial Keratoplasty (DSAEK) Unknown status NCT01357122 Phase 4
4 Ranibizumab for Myopic Neovascularization Unknown status NCT01246089 Phase 4 ranibizumab injection
5 Intravitreal Aflibercept for Neovascular Polypoidal Choroidal Vasculopathy (RIVAL Trial) Unknown status NCT02092532 Phase 4 Rescue Intravitreal Aflibercept Injection
6 Flucinolone Acetonide Implant for Treating Refractory Ocular Behcet's Disease Unknown status NCT00720928 Phase 4 flucinolone acetonide
7 Evaluation of Changes in the Parameters of Optical Coherence Tomography After Intravitreal Injection of Lucentis Unknown status NCT01669447 Phase 4
8 The Efficacy of Methylprednisolone in the Treatment of Patients With Ocular Involvement in Behcet's Disease Unknown status NCT01306955 Phase 4 methylorednisolone
9 Corneal Specular Microscopy in Infectious and Noninfectious Uveitis Completed NCT00789984 Phase 4
10 Multi Center Prospective Registry of Infliximab Use for Childhood Uveitis Completed NCT00589628 Phase 4 infliximab;infliximab
11 Re-implantation of a Fluocinolone Acetonide Implant for Non-infectious Uveitis Affecting the Posterior Segment Completed NCT00543296 Phase 4 0.59 mg Fluocinolone Acetonide implant
12 Multicenter Uveitis Steroid Treatment (MUST) Trial Completed NCT00132691 Phase 4 fluocinolone acetonide intraocular implant;oral corticosteroid with immunosuppressive agents as needed
13 Assessing Cosopt Switch Patients Completed NCT00273442 Phase 4 timolol maleate;dorzolamide/timolol maleate fixed combination
14 Aqueous Flare of a Hydrophobic Acrylic Single-piece Open-loop IOL With Modified Material Surface Properties Completed NCT01767012 Phase 4
15 A Study to Compare Ocular Safety and Tolerability of Eye Drops Containing Prednisolone Acetate in Patients With Intraocular Inflammation After Cataract Surgery Completed NCT00170729 Phase 4 Prednisolone acetate
16 The Effects of α-adrenergic Receptor Antagonists on Choroid and Pupil Completed NCT03144596 Phase 4 Alfuzosin Hydrochloride 10 MG;Tamsulosin Hydrochloride 0.4 MG
17 Intraocular Pressure Immediately Following Intravitreous Injection of Ranibizumab Completed NCT00417703 Phase 4
18 Changes of Macular Pigment and Parameters of Eyes After YAG Laser Treatment in Cases With Capsule Opacification Completed NCT03321253 Phase 4
19 Blood-aqueous Barrier Changes After the Use of Timolol and Prostaglandin Analogues Fixed Combination in Pseudophakic Patients With POAG Completed NCT01978015 Phase 4 travoprost and timolol maleate fixed combination;latanoprost and maleate timolol fixed combination;bimatoprost and timolol maleate fixed combination;dextran and hypromellose
20 Bromfenac to Reduce Inflammation in Patients With Pseudoexfoliation Syndrome After Cataract Surgery Completed NCT02137161 Phase 4 Dexamethasone+Tobramycin eye drop;Bromfenac eye drop
21 TAHOE: Intravitreal Dexamethasone Implant (Ozurdex) for Uveitic Macular Edema Completed NCT01870440 Phase 4 Ozurdex Intravitreal Injection (0.7 mg)
22 Bevacizumab Intravitreal for Myopic Choroidal Neovascularization Completed NCT00797992 Phase 4 Injection
23 Study of H.P. ACTHAR Subcutaneous Gelatin (Gel)(Highly Purified Gel Injection) in Uveitis Patients Completed NCT02764697 Phase 4 H.P. ACTHAR SUBCUTANEOUS GEL INJECTION
24 SD-OCT-guided Intravitreal Ranibizumab Treatment in Choroidal Neovascularization Due to Myopia Completed NCT03409250 Phase 4 Ranibizumab, Lucentis
25 Time Course of Activity Signs at SD-OCT High Frequency Intravitreal Ranibizumab Treatment in CNV Due to AMD Completed NCT03393767 Phase 4 Ranibizumab
26 Saline vs. Lactated Ringers for Emergency Department IV Fluid Resuscitation Completed NCT03133767 Phase 4 Lactated Ringer Solution;Normal Saline 0.9% Infusion Solution Bag
27 Efficacy Study of Ranibizumab on Patients With Age-related Macular Degeneration. Completed NCT01831947 Phase 4
28 Indocyanine Angiographic Changes of Choroidal Neovascularization by Ranibizumab Completed NCT01810042 Phase 4 ranibizumab
29 Comparison of Treatment Regimens Using Ranibizumab: Intensive (Resolution of Intra- and Sub-retinal Fluid) vs Relaxed (Resolution of Primarily Intra-retinal Fluid) Treatment. Completed NCT01972789 Phase 4 Ranibizumab
30 Study to Investigate the Safety and Efficacy of Ranibizumab in Patients With Choroidal Neovascularisation Due to Causes Other Than Age Related Macular Degeneration Completed NCT01628354 Phase 4 Ranibizumab
31 Macular EpiRetinal Brachytherapy Versus Lucentis® Only Treatment (MERLOT) Completed NCT01006538 Phase 4 Ranibizumab
32 Comparison of Safety, Effectiveness and Quality of Life Outcomes Between Labeled Versus "Treat and Extend" Regimen in Turkish Patients With Choroidal Neovascularisation Due to Age-related Macular Degeneration (AMD) Completed NCT01148511 Phase 4 Ranibizumab 0.5 mg
33 Photodynamic Therapy in Occult-Only Lesions (POOL) Completed NCT00135837 Phase 4 Verteporfin for injection
34 Intravitreal Bevacizumab in Recalcitrant Inflammatory Ocular Neovascularization Completed NCT00645697 Phase 4
35 Evaluation of Dosing Interval of Higher Doses of Ranibizumab Completed NCT00533520 Phase 4 ranibizumab
36 Safety and Tolerability of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration Completed NCT00504959 Phase 4 ranibizumab
37 Reduced Fluence Photodynamic Therapy (PDT) With Visudyne in Combination With Lucentis for Age-Related Macular Degeneration Completed NCT00473642 Phase 4 Ranibizumab;Verteporfin;Verteporfin
38 PreView PHP Preferential Hyperacuity Perimeter for the Detection of Choroidal Neovascularization Completed NCT00358345 Phase 4
39 Open Label Study of Acthar SQ Gel Injection in Patients With Active Anterior Uveitis Recruiting NCT02769702 Phase 4 Acthar
40 Study of the Effectiveness of Ozurdex for the Control of Uveitis Recruiting NCT02049476 Phase 4 Dexamethasone pellet
41 Dosing Strategy of Intravitreal Ranibizumab for Pathological Myopia Choroidal Neovascularization Recruiting NCT03042871 Phase 4 0.5mg intravitreal ranibizumab
42 Efficacy of Aflibercept (Eylea®) on Choroidal Neovascularization (Type 3) Recruiting NCT02320474 Phase 4 Aflibercept
43 Efficacy and Safety of H.P. ACTHAR GEL in Adults With Retinal Vasculitis Recruiting NCT03066869 Phase 4 H.P. ACTHAR GEL
44 Topical 2% Ganciclovir Eye Drop for CMV Anterior Uveitis / Endotheliitis Recruiting NCT02943057 Phase 4 2% guttae ganciclovir
45 A Study to Assess the Effects of Certolizumab Pegol on the Reduction of Anterior Uveitis (AU) Flares in Axial Spondyloarthritis Subjects With a Documented History of AU Active, not recruiting NCT03020992 Phase 4 Certolizumab Pegol
46 Topical Treatment for Uveitic Macular Edema Not yet recruiting NCT01939691 Phase 4 Difluprednate 0.05% ophthalmic emulsion;Nepafenac 0.1% ophthalmic solution;Prednisolone acetate 1% ophthalmic suspension
47 PeriOcular and INTravitreal Corticosteroids for Uveitic Macular Edema Trial Suspended NCT02374060 Phase 4 Periocular triamcinolone 40 mg;Intravitreal triamcinolone 4 mg;Dexamethasone intravitreal implant
48 Use of Thalidomide in Chronic Uveitis Terminated NCT00314665 Phase 4 Thalidomide
49 Efficacy Study of Methotrexate to Treat Sarcoid-associated Uveitis Terminated NCT00918554 Phase 4 Methotrexate;Placebo
50 A Study Of Early Markers Of Choroidal Neovascularization Terminated NCT00902785 Phase 4

Search NIH Clinical Center for Uveal Diseases

Genetic Tests for Uveal Diseases

Anatomical Context for Uveal Diseases

MalaCards organs/tissues related to Uveal Diseases:

38
Eye, Endothelial, Liver, Testes, T Cells, Skin, Bone

Publications for Uveal Diseases

Articles related to Uveal Diseases:

# Title Authors Year
1
Golden retriever cystic uveal disease: a longitudinal study of iridociliary cysts, pigmentary uveitis, and pigmentary/cystic glaucoma over a decade in western Canada. ( 26119416 )
2016
2
Cytokines: their role in uveal disease. ( 9349412 )
1997
3
A-mode echography in the diagnosis of uveal disease. ( 880517 )
1977
4
Methotrexate treatment of uveal disease. ( 5904740 )
1966
5
Retinal lesions associated with uveal disease. I. ( 13372709 )
1956
6
The influence of hypersensitivity on endogenous uveal disease. ( 20288588 )
1947
7
The influence of hypersensitivity on endogenous uveal disease. ( 20279194 )
1946
8
Concerning the Use of Diphtheria Antitoxin in Post-Operative Infections and Acute Uveal Disease. ( 16692610 )
1922

Variations for Uveal Diseases

Expression for Uveal Diseases

Search GEO for disease gene expression data for Uveal Diseases.

Pathways for Uveal Diseases

GO Terms for Uveal Diseases

Sources for Uveal Diseases

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....